[{"data":1,"prerenderedAt":177},["ShallowReactive",2],{"drug-pancrelipase":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":68,"warnings":69,"renal":77,"monitoring":78,"interactions":79,"review":80,"examples":83,"atc":89,"iran":91,"links":119,"populations":137,"usApproval":172},"pancrelipase",1,{"fa":7,"en":8},"پانکرلیپاز (کرئون)","Pancrelipase","alimentary-metabolism",{"fa":11,"en":12},"آنزیم پانکراس","Pancreatic enzymes",[14],{"name":15,"market":16},"Creon","US",[18,19,20,21],"creon","کرئون","پانکراتین","pancreatin",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"cap-12000","capsule","oral","Creon 12,000 lipase units capsule",{"amount":29,"unit":30,"perUnit":25,"scored":31},12000,"unit",false,[16],[34],{"source":35,"section":36},"fda-creon","3",[38],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":30,"dose":49,"refs":52,"limits":55,"notes":61},"epi","pancreatic-insufficiency",{"fa":42,"en":43},"نارسایی پانکراس — ۴ سال به بالا: شروع ۵۰۰ واحد لیپاز\u002Fkg در هر وعده","Pancreatic insufficiency — ≥4 y: start 500 lipase units\u002Fkg per meal",{"minAge":45},{"value":46,"unit":47},4,"year","weightBased",{"perKgPerDose":50,"intervalHours":51},500,8,[53],{"source":35,"section":54},"2.2",{"maxPerKgPerDose":56,"maxPerKgPerDay":57,"refs":58},2500,10000,[59],{"source":35,"section":60},"2",[62],{"text":63,"refs":66},{"fa":64,"en":65},"نصف دوز با میان‌وعده. بیش از ۲۵۰۰ واحد\u002Fkg\u002Fوعده یا ۱۰٬۰۰۰ واحد\u002Fkg\u002Fروز بدون بررسی بیشتر نه (خطر فیبروزان کولونوپاتی). کپسول کامل بلعیده شود.","Half dose with snacks. Do not exceed 2,500 units\u002Fkg\u002Fmeal or 10,000 units\u002Fkg\u002Fday without investigation (fibrosing colonopathy). Swallow capsules whole.",[67],{"source":35,"section":60},[],[70],{"text":71,"refs":74},{"fa":72,"en":73},"فیبروزان کولونوپاتی با دوزهای بالا؛ کپسول خرد یا جویده نشود.","Fibrosing colonopathy with high doses; do not crush or chew.",[75],{"source":35,"section":76},"5",[],[],[],{"status":81,"reviewer":82,"date":82},"unverified",null,[84],{"regimen":39,"formulation":24,"input":85,"expect":88},{"ageYears":86,"weightKg":87},10,24,{"perDose":29,"tabletsPerDoseRounded":5},[90],"A09AA02",{"status":92,"forms":93,"refs":114},"registered",[94,98,102,106,110],{"code":95,"en":96,"fa":97},"12312","PANCREATIN CAP","کپسول پانکراتین",{"code":99,"en":100,"fa":101},"00945","PANCREATIN FORTE 700MG TAB","قرص پانکراتین فورت ۷۰۰ میلی‌گرم",{"code":103,"en":104,"fa":105},"00944","PANCREATIN TAB","قرص پانکراتین",{"code":107,"en":108,"fa":109},"50404","PANCREATIN CAPSULE ORAL 10000 [iU]","کپسول پانکراتین ۱۰۰۰۰ واحد بین‌المللی",{"code":111,"en":112,"fa":113},"51916","PANCREATIN CAPSULE ORAL 40000 [iU]","کپسول پانکراتین ۴۰۰۰۰ واحد بین‌المللی",[115],{"source":116,"section":117,"url":118},"darooyab-generic","G-4540\u002FPancreatin","https:\u002F\u002Fwww.darooyab.ir\u002FG-4540\u002FPancreatin",[120,124,128,131,134],{"kind":121,"url":122,"label":123},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=020725","BLA020725",{"kind":125,"url":126,"label":127},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=073201aa-556d-4a70-918e-84e9616fd88d","FDA Creon",{"kind":129,"url":130,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa604035.html",{"kind":132,"url":133,"label":90},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A09AA02",{"kind":135,"url":118,"label":136},"darooyab","Pancreatin",{"pregnancy":138,"lactation":147,"pediatric":155,"geriatric":164},{"level":139,"text":140,"quote":143,"refs":144},"ok",{"fa":141,"en":142},"برچسب: جذب سیستمیک ناچیز؛ مواجهه جنین انتظار نمی‌رود.","Label: minimal systemic absorption; fetal exposure not expected.","Pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug.",[145],{"source":35,"section":146},"8.1",{"level":139,"text":148,"quote":151,"refs":152},{"fa":149,"en":150},"برچسب: مواجهه شیرخوار انتظار نمی‌رود.","Label: infant exposure not expected.","Pancrelipase is minimally absorbed systemically following oral administration; therefore, maternal use is not expected to result in clinically relevant exposure of breastfed infants to the drug.",[153],{"source":35,"section":154},"8.2",{"level":156,"text":157,"quote":160,"refs":161},"caution",{"fa":158,"en":159},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of CREON for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients.",[162],{"source":35,"section":163},"8.4",{"level":156,"text":165,"quote":168,"refs":169},{"fa":166,"en":167},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical studies of CREON did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients.",[170],{"source":35,"section":171},"8.5",{"kind":173,"refs":174,"id":123},"BLA",[175],{"source":35,"section":176},"SPL approval \u002F marketing category",1792092042140]